At the surface, the immune response to a flu virus is simple. Some cells recognize the pathogen and send a signal to the ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

T-bet is a transcription factor, one of the control proteins in the cell nucleus that can turn specific groups of genes on ...

Circulate Health, a Seattle health longevity startup, today announced $12 million in seed funding to expand its plasma ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...

Multiple myeloma is a cancer of the plasma cells in which abnormal plasma cells multiply uncontrollably in the bone marrow and occasionally in other parts of the body. It is the second most common ...

In a significant step toward improving targeted cancer therapy, researchers from Japan have developed a novel nanocarrier ...

The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous ...

A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first. It can halt the blood cancer myeloma for nearly three times longer ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults ...